Autolus Therapeutics PLC - American Depositary Shares (AUTL) closed at $0.91 on November 20, 2026, down 7.4% from the previous close, on volume of 3,776,405 shares (30-day average 2,436,767).
Data as of November 20, 2026.
Globe Newswire (Tue, 10-Nov 4:05 PM ET)
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference
Globe Newswire (Mon, 9-Nov 7:15 AM ET)
Globe Newswire (Wed, 4-Nov 9:15 AM ET)
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 3-Nov 4:45 PM ET)
Globe Newswire (Mon, 26-Oct 4:15 PM ET)
Globe Newswire (Mon, 5-Oct 8:30 AM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
AUTL Raises FY26 Guidance as AUCATZYL Revenue Surges 119%—Gross Margins Hit 55% in Q2
Market Chameleon (Tue, 11-Aug 7:19 AM ET)
Market Chameleon (Mon, 3-Aug 6:31 AM ET)
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Autolus Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AUTL.
As of November 20, 2026, AUTL stock price declined to $0.91 with 3,776,405 million shares trading.
AUTL has a beta of 3.30, meaning it tends to be more sensitive to market movements. AUTL has a correlation of 0.30 to the broad based SPY ETF.
AUTL has a market cap of $241.65 million. This is considered a Small Cap stock.
Last quarter Autolus Therapeutics PLC - American Depositary Shares reported $41 million in Revenue and -$.21 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.03.
In the last 3 years, AUTL traded as high as $7.45 and as low as $.90.
The top ETF exchange traded funds that AUTL belongs to (by Net Assets): IBB, GWX, QQQS, APIE, IBBQ.
AUTL has underperformed the market in the last year with a price return of -28.6% while the SPY ETF gained +5.2%. AUTL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -64.3% and -28.0%, respectively, while the SPY returned -10.1% and -5.9%, respectively.
AUTL support price is $.93 and resistance is $1.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUTL shares will trade within this expected range on the day.